An interventional study of Robotic-assisted nipple-sparing mastectomy and Endoscopic-assisted nipple-sparing mastectomy in Breast Neoplasms, sponsored by Guangzhou Women and Children's Medical Center. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Guangzhou Women and Children's Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.
Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 320th largest by planned enrollment of the 1,525 interventional ones that give a count, is one of 192 that started in 2026, is one of 328 with no phase, reaches primary completion later than 734 of the 1,067 other live ones, and was the 1,916th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:
First Affiliated Hospital of Guangxi Medical University · Sites in China
Ages 18–70 · Women only
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–70 · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80 · Healthy volunteers
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18+ · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,936 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 281 · Phase 2 643 · Phase 3 372 · Phase 4 51
First in 1997; this study’s year is marked. 192 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 374 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 120 across the 1,525 interventional studies, 240 across the 409 observational. Of the 451 that completed or were terminated, 77 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
490 of 1,936 have an industry lead sponsor. The 10 most frequent:
Guangzhou Women and Children's Medical Center is the lead sponsor of 58 studies on the registry; 30 are open to participants now.
Guangzhou Women and Children's Medical Center has 6 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
248 of the studies in Breast Neoplasms with a site in China that are under way reach primary completion within a year, 42 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06954961Phase 3InventisBio Co., LtdA Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | 2026-11-30 |
| NCT06968585Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy | 2026-11-30 |
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT04639986Phase 3Gilead SciencesAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | 2026-12 |
| NCT04290793Phase 3Hebei Medical University Fourth HospitalNeoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer | 2026-12-01 |
Add all 248 to your calendar (.ics) → With an account.
Among the 1,936 studies in Breast Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, prospective, randomized parallel controlled two arm clinical trial, designed to systematically evaluate impact of robotic versus endoscopic surgery on breast nerve function in patients undergoing nipple sparing mastectomy for breast cancer. The study will comprehensively assess the neurological functional outcomes, oncological safety, quality of life and sexual health, perioperative efficacy, surgical complications, and health economic value of the two minimally invasive approaches.
This study has been approved by the Institutional Review Board of the Affiliated Women and Children's Medical Center of Guangzhou Medical University. Written informed consent will be obtained from all eligible participants prior to enrollment. All patient data will be anonymized and kept strictly confidential. Statistical analyses will be performed using SPSS 27.0 software, with a P value \< 0.05 set as the threshold for statistical significance.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo robotic-assisted nipple-sparing mastectomy for breast cancer.
Procedure: Robotic-assisted nipple-sparing mastectomy
Patients undergo endoscopic-assisted nipple-sparing mastectomy for breast cancer.
Procedure: Endoscopic-assisted nipple-sparing mastectomy
Robotic-assisted nipple-sparing mastectomy for breast cancer.
Endoscopic-assisted nipple-sparing mastectomy for breast cancer.
Tactile pressure sensation of the nipple-areola complex at 6 months postoperatively
Tactile pressure sensation will be measured using Semmes-Weinstein monofilaments. The examiner will apply the device to the nipple-areola complex, using filaments of incrementally increasing force (0.07 g, 0.4 g, 2.0 g, 4.0 g, 300 g), and record the lightest filament detectable by the patient.
Time frame: 12 months postoperatively
Positive surgical margin rate
Time frame: Intraoperative / postoperative (2 weeks after surgery)
Tactile pressure sensation of the nipple-areola complex and breast skin at multiple postoperative time points
Tactile pressure sensation will be measured using Semmes-Weinstein monofilaments. The examiner will apply the device to the nipple-areola complex and predefined quadrants of the surrounding breast skin, using filaments of incrementally increasing force (0.07 g, 0.4 g, 2.0 g, 4.0 g, 300 g), and record the lightest filament detectable by the patient.
Time frame: Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months postoperatively
Temperature sensation of the nipple-areola complex and breast skin
Temperature sensation will be assessed at the nipple-areola complex and predefined quadrants of the breast skin. Cold sensation is tested with an ice hammer, and warm sensation is tested using the heating mode of a massage device.
Time frame: Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months postoperatively
Erection function of the nipple-areola complex
Nipple erection function will be evaluated by stimulation of the nipple-areola complex using the vibration mode of a massage device.
Time frame: Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months postoperatively
Patient-reported outcomes
Patient-reported breast-specific sensory function, quality of life and sexual well-being will be assessed using the BREAST-Q™ Sensation Module (Pre- and Postoperative) Version 2.0 and BREAST-Q™ Breast Cancer Core Scale (Pre- and Postoperative) Version 2.0 (Sexual Well-being subscale). All subscales yield Rasch-transformed scores ranging from 0 (worst outcome) to 100 (best outcome): higher scores represent better breast sensory function, fewer breast symptoms, less negative quality-of-life impact from breast sensation alteration, and superior sexual well-being, respectively.
Time frame: Baseline, 1 week, 2 weeks, 1 month, 3 months, 6 months, 12 months, 18 months and 24 months postoperatively
Disease-free survival (DFS)
Disease-free survival (DFS), defined as the time from surgery to the first occurrence of recurrence, metastasis, or death. DFS will be compared between the two study groups.
Time frame: Following surgery up to 3 years
Overall survival (OS)
Overall survival (OS), defined as the time from surgery to death from any cause. OS will be compared between the two study groups.
Time frame: Following surgery up to 3 years
Recurrence and Metastasis Events
The incidence of axillary recurrence, locoregional recurrence, and distant metastasis is compared between the two groups, with all events confirmed by histopathological or radiological evidence.
Time frame: Following surgery up to 3 years
Postoperative Complications
The incidence of postoperative complications, including but not limited to: nipple-areola complex necrosis, infection, seroma, hematoma, is compared between the two groups.
Time frame: Within 30 days post-surgery and at long-term follow-up assessments
Cost-Utility Analysis
A cost-utility analysis will be performed to compare the two groups. The incremental cost-utility ratio (ICUR) will be calculated to evaluate the cost-utility of the two surgical strategies.
Time frame: Following surgery up to 3 years
Operative Time
Operative time (minutes) is compared between the two groups.
Time frame: During surgery, recorded in the operative note
Axillary operation
Record the axillary surgical procedure of the two groups (None/Sentinel lymph node dissection/Axillary lymph node dissection)
Time frame: During surgery, recorded in the operative note
Intraoperative Blood Loss
Intraoperative Blood Loss(mL) is compared between the robotic-assisted and endoscopic-assisted axillary lymph node dissection groups.
Time frame: During surgery, recorded in the operative note
Postoperative Recovery Parameters
Length of postoperative hospital stay (days) and duration of postoperative drainage (days) are compared between the robotic-assisted and endoscopic-assisted groups.
Time frame: During index hospitalization and within 30 days post-surgery
Plan to share: No — Individual participant data will not be shared due to the prospective design of this study and concerns regarding patient privacy and confidentiality. The data are collected in accordance with the study protocol under the approval of the ethics committee, with written informed consent obtained from all enrolled participants, and the original consent forms do not include provisions for data sharing with external researchers. Therefore, IPD sharing is not planned. However, summarized data and analytical codes may be available from the corresponding author upon reasonable request, subject to institutional and ethical approval.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 12 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guangzhou Women and Children's Medical Center